See more : Bubblr Inc. (BBLR) Income Statement Analysis – Financial Results
Complete financial analysis of Paramount Group, Inc. (PGRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paramount Group, Inc., a leading company in the REIT – Office industry within the Real Estate sector.
You may be interested
- RattanIndia Power Limited (RTNPOWER.NS) Income Statement Analysis – Financial Results
- TWOSTONE&Sons Inc. (7352.T) Income Statement Analysis – Financial Results
- Keynote Financial Services Limited (KEYFINSERV.NS) Income Statement Analysis – Financial Results
- Rivian Automotive, Inc. (RIVN) Income Statement Analysis – Financial Results
- Ocumension Therapeutics (1477.HK) Income Statement Analysis – Financial Results
Paramount Group, Inc. (PGRE)
About Paramount Group, Inc.
Headquartered in New York City, Paramount Group, Inc. is a fully-integrated real estate investment trust that owns, operates, manages, acquires and redevelops high-quality, Class A office properties located in select central business district submarkets of New York City and San Francisco. Paramount is focused on maximizing the value of its portfolio by leveraging the sought-after locations of its assets and its proven property management capabilities to attract and retain high-quality tenants.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 742.79M | 740.38M | 726.79M | 714.24M | 769.18M | 758.96M | 718.97M | 683.34M | 662.41M | 419.89M | 58.65M | 54.29M | 56.99M |
| Cost of Revenue | 544.61M | 277.42M | 265.44M | 267.59M | 274.84M | 274.08M | 266.14M | 250.04M | 244.75M | 16.20M | 16.20M | 15.40M | 14.66M |
| Gross Profit | 198.18M | 462.96M | 461.35M | 446.65M | 494.34M | 484.88M | 452.83M | 433.30M | 417.65M | 403.70M | 42.46M | 38.89M | 42.34M |
| Gross Profit Ratio | 26.68% | 62.53% | 63.48% | 62.54% | 64.27% | 63.89% | 62.98% | 63.41% | 63.05% | 96.14% | 72.39% | 71.63% | 74.28% |
| Research & Development | 0.00 | -0.03 | 0.01 | -0.02 | 0.01 | 0.03 | 0.16 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 61.99M | 59.49M | 59.13M | 64.92M | 68.56M | 57.56M | 58.95M | 50.64M | 42.06M | 33.50M | 56.89M | 45.93M | 103.91M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 61.99M | 59.49M | 59.13M | 64.92M | 68.56M | 57.56M | 58.95M | 50.64M | 42.06M | 33.50M | 56.89M | 45.93M | 103.91M |
| Other Expenses | 0.00 | 232.52M | 232.49M | 235.20M | 248.35M | 258.23M | 266.04M | 269.45M | 294.62M | 0.00 | 322.00K | 16.67M | 784.00K |
| Operating Expenses | 61.99M | 292.00M | 291.62M | 300.12M | 316.90M | 315.79M | 324.99M | 320.09M | 336.68M | 33.50M | 72.10M | 62.60M | 119.92M |
| Cost & Expenses | 606.60M | 569.43M | 557.06M | 567.70M | 591.74M | 589.87M | 591.12M | 570.13M | 581.43M | 49.70M | 88.30M | 78.00M | 134.58M |
| Interest Income | 8.62M | 5.17M | 3.02M | 2.05M | 5.48M | 5.38M | 1.26M | 774.00K | 871.00K | 3.55M | 2.36M | 2.05M | |
| Interest Expense | 146.77M | 143.86M | 142.01M | 134.93M | 137.36M | 136.63M | 132.57M | 150.94M | 168.37M | 29.37M | 36.91M | 34.20M | |
| Depreciation & Amortization | 250.64M | 569.43M | 557.06M | 604.06M | 575.36M | 591.34M | 593.98M | 535.59M | 294.62M | 10.58M | 10.58M | 10.10M | 10.70M |
| EBITDA | 27.54M | 354.15M | 381.12M | 356.85M | 407.35M | 425.85M | 391.03M | 417.20M | 441.00M | 212.49M | 343.24M | 182.77M | 447.29M |
| EBITDA Ratio | 3.71% | 47.83% | 52.44% | 49.96% | 52.96% | 56.46% | 53.21% | 56.97% | 57.87% | 70.17% | -24.83% | -14.42% | -103.33% |
| Operating Income | 136.19M | 121.64M | 148.63M | 120.96M | 159.01M | 121.62M | 123.19M | 107.94M | 70.62M | 331.59M | 331.59M | 168.81M | 471.36M |
| Operating Income Ratio | 18.34% | 16.43% | 20.45% | 16.94% | 20.67% | 16.03% | 17.13% | 15.80% | 10.66% | 78.97% | 565.34% | 310.94% | 827.05% |
| Total Other Income/Expenses | -506.07M | -146.57M | -372.40M | -133.59M | -165.87M | -99.49M | -10.84M | -104.08M | -46.91M | -130.51M | -17.72M | -25.94M | 9.08M |
| Income Before Tax | -369.88M | -24.93M | 5.70M | -12.63M | -29.29M | 22.13M | 112.35M | 3.85M | 23.71M | 313.87M | 313.87M | 146.72M | 443.93M |
| Income Before Tax Ratio | -49.80% | -3.37% | 0.78% | -1.77% | -3.81% | 2.92% | 15.63% | 0.56% | 3.58% | 74.75% | 535.13% | 270.26% | 778.91% |
| Income Tax Expense | 1.43M | 3.27M | 3.64M | 1.49M | 312.00K | 3.14M | 5.18M | 1.79M | 2.57M | -11.03M | 11.03M | 6.98M | 42.97M |
| Net Income | -259.74M | -28.20M | 2.06M | -14.12M | -29.60M | 9.15M | 86.38M | -9.93M | -4.42M | 324.90M | 16.51M | 2.30M | 53.88M |
| Net Income Ratio | -34.97% | -3.81% | 0.28% | -1.98% | -3.85% | 1.21% | 12.01% | -1.45% | -0.67% | 77.38% | 28.16% | 4.23% | 94.53% |
| EPS | -1.20 | -0.13 | 0.01 | -0.06 | -0.13 | 0.04 | 0.37 | -0.05 | -0.02 | 1.53 | 0.07 | 0.01 | 0.22 |
| EPS Diluted | -1.20 | -0.13 | 0.01 | -0.06 | -0.13 | 0.04 | 0.37 | -0.05 | -0.02 | 1.53 | 0.07 | 0.01 | 0.22 |
| Weighted Avg Shares Out | 216.92M | 221.31M | 218.70M | 222.44M | 231.54M | 239.53M | 236.37M | 218.05M | 212.11M | 212.11M | 244.00M | 244.00M | 244.00M |
| Weighted Avg Shares Out (Dil) | 216.92M | 221.31M | 218.70M | 222.44M | 231.54M | 239.56M | 236.40M | 218.05M | 212.11M | 212.11M | 244.00M | 244.00M | 244.00M |
Paramount Global-B (PARA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Paramount Global-B (PARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ariat and Yellowstone Launch Western Collab That's Pure Dutton Ranch Style Designed with Johnetta Boone
Designed by Ariat in collaboration with Yellowstone costume designer Johnetta Boone, fans can see the stunning limited-edition collection in the hit Paramount Network show's new season and shop the looks through both Ariat and Amazon. Designed by Ariat in collaboration...
Paramount Group, Inc. (PGRE) Q3 2024 Earnings Call Transcript
Paramount Group, Inc. (NYSE:PGRE ) Q3 2024 Earnings Call October 31, 2024 10:00 AM ET Company Participants Tom Hennessy - Vice President, Business Development and Investor Relations Albert Behler - Chairman, Chief Executive Officer and President Wilbur Paes - Chief...
David Ellison Will Hold 100% Of Family Interest In Paramount When Skydance Deal Closes
An amended FCC filing by Skydance today says that David Ellison will hold 100% of the Ellison family's interest in Paramount once that deal closes. The clarification is an attempt to allay concern that control will reside with his father,...
Here's Why Paramount Global-B (PARA) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is the Options Market Predicting a Spike in Paramount Global (PARAA) Stock?
Investors need to pay close attention to Paramount Global (PARAA) stock based on the movements in the options market lately.
Paramount Announces Release Date for Third Quarter 2024 Results
NEW YORK--(BUSINESS WIRE)--Paramount Group, Inc. (NYSE: PGRE) (“Paramount” or the “Company”) announced today that it will file its quarterly report on Form 10-Q for the quarter ended September 30, 2024 with the U.S. Securities and Exchange Commission and release its...
Paramount Global to Report Third Quarter Financial Results on November 8, 2024
NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Paramount Global (NASDAQ: PARA, PARAA) announced today that it will report third quarter financial results on Friday, November 8, 2024. The company will conduct a conference call at 8:30 a.m.
Fast-paced Momentum Stock Paramount Global (PARAA) Is Still Trading at a Bargain
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Paramount Global (PARAA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum...
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors,...
Source: https://incomestatements.info
Category: Stock Reports